Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents
Authors:
Open Access
- 10 April 2023
- journal article
- research article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 40, 100478
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapyBMC Research Notes, 2013
- Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapyBone, 2013
- Bisphosphonate Use and Atypical Fractures of the Femoral ShaftNew England Journal of Medicine, 2011
- Metastasis and bone loss: Advancing treatment and preventionCancer Treatment Reviews, 2010
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral ResearchJournal of Bone and Mineral Research, 2010
- Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fracturesJournal of Bone and Mineral Research, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking AlendronateNew England Journal of Medicine, 2008
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesionCancer, 2003